Verici Dx Plc (GB:VRCI) has released an update.
Verici Dx Plc, a clinical diagnostics developer for organ transplants, reports a transformative 2023 with a major licensing agreement with Thermo Fisher Scientific and the successful launch of two diagnostic products, Tutivia and Clarava. The company has also reinforced its financial position through fundraising and forecasts an extended cash runway into 2026. This progress marks Verici Dx’s shift from research to a commercial-stage company with a focus on growth and strategic initiatives in the coming year.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.
